MedTrace Logo

Valproic Acid and Its Effects on HIV Latent Reservoirs

NCT00289952 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-03-15

No results posted yet for this study

Summary

The purpose of this study is to examine whether the co-administration of valproic acid (Epival®), with highly active antiretroviral therapy (HAART) can reduce the size of HIV latent reservoirs in infected CD4 cells.

Conditions

  • HIV Infections

Interventions

DRUG

Valproic Acid

Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.

DRUG

HAART

As per standard of care.

Sponsors & Collaborators

  • Canadian Foundation for AIDS Research (CANFAR)

    collaborator OTHER

  • CIHR Canadian HIV Trials Network

    collaborator NETWORK

  • Jean-Pierre Routy

    lead OTHER

Principal Investigators

  • Jean-Pierre Routy, MD · Royal-Victoria Hospital/McGill University Health Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00289952 on ClinicalTrials.gov